TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA approved asundexian, sold as Sunharbo, for use with antiplatelet therapy to lower the risk of another stroke in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. In the OCEANIC-Stroke trial, ischemic stroke occurred in 6.2% of participants receiving the drug and 8.4% receiving placebo through 780 days; major bleeding was not significantly higher. The drug is not approved to prevent stroke in people with atrial fibrillation.
The FDA has approved asundexian (Sunharbo) for use with antiplatelet therapy to reduce the risk of another stroke in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack. The agency announced the decision on Monday, making asundexian the first approved factor XIa inhibitor, based on results from the phase III OCEANIC-Stroke trial.
Asundexian is an oral, direct-acting small-molecule inhibitor of factor XIa (FXIa), a protein involved in blood clotting. The FDA indication is for use alongside antiplatelet treatment in the specified patient groups; it is not an approval for all people who have had a stroke or transient ischemic attack.
In OCEANIC-Stroke, ischemic stroke occurred in 6.2% of participants taking asundexian and 8.4% of those taking placebo during follow-up of up to 780 days. The trial report described this as a 26% relative reduction, with a hazard ratio of 0.74 (95% CI 0.65-0.84). The absolute event rates and study period help put that relative reduction in context.
Major bleeding was reported in 1.9% of participants receiving the 50-mg once-daily dose and 1.7% receiving placebo (HR 1.10, 95% CI 0.85-1.44). The trial did not find a statistically significant increase in major bleeding. That finding does not establish that bleeding risk is absent for every patient or in every circumstance.
A New Option After Certain Strokes
For eligible adults, the approval adds a treatment option intended to lower the chance of a recurrent ischemic stroke while being taken with antiplatelet therapy. The trial results are relevant because preventing another stroke requires weighing the potential reduction in clot-related events against the possibility of serious bleeding.
The reported difference in major bleeding was not statistically significant in OCEANIC-Stroke, but the confidence interval around the estimate does not prove that the risk is identical between groups. Clinicians and patients will need to consider the approved indication, other medicines, medical history and procedure plans when evaluating the treatment. The FDA described the decision as a new option for secondary prevention, not a replacement for individualized care.
Products Worth Considering
Oral-B iO5 Rechargeable Electric Toothbrush with 5 Cleaning Modes and Travel Case, White
Philips Sonicare 6500 Series Rechargeable Electric Toothbrush with 2 Brush Heads, White
Bowflex SelectTech 840 Adjustable Kettlebell
As an affiliate, we earn on qualifying purchases.
Trial Results and Use Limits
The approval was supported by the large phase III OCEANIC-Stroke trial, which compared asundexian with placebo for secondary prevention after qualifying non-cardioembolic ischemic stroke or high-risk TIA. The reported outcomes cover ischemic stroke through 780 days and major bleeding among participants assigned to the 50-mg daily dose.
Asundexian’s approval is limited by both its indication and safety-related instructions. It is not approved for stroke prevention in people with atrial fibrillation. The drug did not show efficacy in the phase III OCEANIC-AF trial, which was stopped early for lack of efficacy, according to the report.
The FDA also advises against taking asundexian with combined P-glycoprotein and strong CYP3A4 inducers, including carbamazepine, rifampin and St. John’s Wort, because those drugs may reduce its effectiveness. It is not recommended for people with moderate or severe hepatic impairment. The agency says it should be withheld for at least 24 hours before an invasive procedure and for at least 24 hours after thrombolysis for acute ischemic stroke.
““Stroke is a leading cause of disability and death in the United States, and survivors are at risk of having another stroke.””
— Hylton Joffe, MD, MMSc, director of the FDA’s Office of Cardiology, Hematology, Endocrinology, and Nephrology
Limits of the Evidence and Indication
The reported trial figures do not answer how the treatment will perform across every patient subgroup or over periods beyond the 780-day follow-up cited in the results. The source material does not provide details on the size of subgroup effects, longer-term outcomes, or how the FDA’s full prescribing information addresses individual clinical situations.
The approval also does not extend to people with atrial fibrillation, and the OCEANIC-AF result underscores that findings in one stroke-prevention population cannot be assumed to apply to another. The available information does not specify when the drug will become widely available, its price, or how clinicians will incorporate it into existing treatment plans.
Prescribing and Further Stroke Trials
Clinicians and patients can now assess the FDA-approved indication and prescribing instructions when considering secondary prevention after a qualifying stroke or high-risk TIA. The key practical questions include whether a patient fits the indicated population, which other medicines they take, whether they have liver impairment, and whether an invasive procedure or thrombolysis is planned.
Further research may add evidence about use in different patient groups and longer follow-up. Another FXIa inhibitor, milvexian, remains under investigation for secondary stroke prevention, according to the report. No trial results or regulatory decision for that drug are provided in the source material.
Key Questions
Who is asundexian approved for?
The FDA approved it with antiplatelet therapy to reduce stroke risk in adults after a recent mild-to-moderate non-cardioembolic ischemic stroke or a high-risk transient ischemic attack.
How did asundexian perform in the trial?
Through 780 days, ischemic stroke occurred in 6.2% of participants taking asundexian and 8.4% taking placebo. The trial reported a 26% relative reduction; these results apply to the study population and follow-up period.
Did the trial show more major bleeding?
Major bleeding occurred in 1.9% of participants on the 50-mg daily dose and 1.7% on placebo. The difference was not statistically significant; that does not mean bleeding risk is absent.
Can people with atrial fibrillation use asundexian to prevent stroke?
Asundexian is not approved for stroke prevention in people with atrial fibrillation. The OCEANIC-AF trial was stopped early for lack of efficacy, according to the report.
What medicines or conditions affect its use?
The FDA advises against combining it with certain P-glycoprotein and strong CYP3A4 inducers, and does not recommend it for moderate or severe hepatic impairment. It should also be withheld around invasive procedures and after thrombolysis as specified by the FDA. Patients should consult a qualified health professional about treatment decisions.
Source: medpagetoday.com
